clevercast
{"PLE04":{"id":"WdekGw","strictid":"PLE04","name":"PLE04","description":"","account_id":"2bK6rw","ts":0},"PLE05":{"id":"W9mpyj","strictid":"PLE05","name":"PLE05 Closing Ceremony + Concert","description":"","account_id":"2bK6rw","ts":1638855000},"SAT09":{"id":"VvyakX","strictid":"SAT09","name":"SAT09","description":"","account_id":"2bK6rw","ts":1638889200},"SPI07":{"id":"WwGDRw","strictid":"SPI07","name":"SPI07","description":"","account_id":"2bK6rw","ts":1638874920},"SCS14":{"id":"2avEmE","strictid":"SCS14","name":"SCS14","description":"","account_id":"2bK6rw","ts":1638874920},"SCS13":{"id":"A6nmKN","strictid":"SCS13","name":"SCS13","description":"","account_id":"2bK6rw","ts":1638874920},"KEY09":{"id":"Wlqkxg","strictid":"KEY09","name":"KEY09","description":"","account_id":"2bK6rw","ts":1638874920},"KEY06":{"id":"AGZbol","strictid":"KEY06","name":"KEY06","description":"","account_id":"2bK6rw","ts":1638873120},"KEY01":{"id":"AR1vr7","strictid":"KEY01","name":"KEY01","description":"","account_id":"2bK6rw","ts":1638871320},"PLE03":{"id":"VyOE09","strictid":"PLE03","name":"PLE03","description":"","account_id":"2bK6rw","ts":1638867600},"WEB05":{"id":"AKYxLw","strictid":"WEB05","name":"WEB05","description":"","account_id":"2bK6rw","ts":1638824520},"WEB04":{"id":"V316Xb","strictid":"WEB04","name":"WEB04","description":"","account_id":"2bK6rw","ts":1638817320},"KEY05":{"id":"WNKJlG","strictid":"KEY05","name":"KEY05","description":"","account_id":"2bK6rw","ts":1638811920},"SPI06":{"id":"VBXxdo","strictid":"SPI06","name":"SPI06","description":"","account_id":"2bK6rw","ts":0},"SCS12":{"id":"VYeD58","strictid":"SCS12","name":"SCS12","description":"","account_id":"2bK6rw","ts":1638810120},"SCS10":{"id":"VDrPkz","strictid":"SCS10","name":"SCS10","description":"","account_id":"2bK6rw","ts":1638810120},"KEY03":{"id":"W9mpEj","strictid":"KEY03","name":"KEY03","description":"","account_id":"2bK6rw","ts":1638810120},"SAT08":{"id":"VvyaNX","strictid":"SAT08","name":"SAT08","description":"","account_id":"2bK6rw","ts":0},"SAT07":{"id":"WwGD3w","strictid":"SAT07","name":"SAT07","description":"","account_id":"2bK6rw","ts":0},"SPI05":{"id":"VznBKn","strictid":"SPI05","name":"SPI05","description":"","account_id":"2bK6rw","ts":1638788520},"SCS11":{"id":"ApYQ5M","strictid":"SCS11","name":"SCS11","description":"","account_id":"2bK6rw","ts":1638788520},"SCS09":{"id":"2MnrZe","strictid":"SCS09","name":"SCS09","description":"","account_id":"2bK6rw","ts":1638788520},"SPI04":{"id":"Wlqkpg","strictid":"SPI04","name":"SPI04","description":"","account_id":"2bK6rw","ts":1638781320},"SCS08":{"id":"ALoQw5","strictid":"SCS08","name":"SCS08","description":"","account_id":"2bK6rw","ts":1638781320},"SCS07":{"id":"AGZbgl","strictid":"SCS07","name":"SCS07","description":"","account_id":"2bK6rw","ts":1638781320},"WEB03":{"id":"WokLe9","strictid":"WEB03","name":"WEB03","description":"","account_id":"2bK6rw","ts":1638738120},"SAT04":{"id":"Ak6yrj","strictid":"SAT04","name":"SAT04","description":"","account_id":"2bK6rw","ts":0},"SAT06":{"id":"WdekLm","strictid":"SAT06","name":"SAT06","description":"","account_id":"2bK6rw","ts":0},"KEY08":{"id":"WNKJwG","strictid":"KEY08","name":"KEY08","description":"","account_id":"2bK6rw","ts":1638716520},"KEY10":{"id":"2bzB4G","strictid":"KEY10","name":"KEY10","description":"","account_id":"2bK6rw","ts":0},"SCS04":{"id":"VPxn5l","strictid":"SCS04","name":"SCS04","description":"","account_id":"2bK6rw","ts":1638716520},"SCS03":{"id":"WdekLP","strictid":"SCS03","name":"SCS03","description":"","account_id":"2bK6rw","ts":1638716520},"SPI02":{"id":"21a6D6","strictid":"SPI02","name":"SPI02","description":"Societal impact of influenza and COVID-19","account_id":"2bK6rw","ts":1638702120},"KEY02":{"id":"VznBQJ","strictid":"KEY02","name":"KEY02","description":"","account_id":"2bK6rw","ts":1638702000},"SCS06":{"id":"ApYQJq","strictid":"SCS06","name":"SCS06","description":"Innate and adaptive immunity towards influenza, RSV disease and COVID-19","account_id":"2bK6rw","ts":1638702120},"SPI01":{"id":"AZzDlk","strictid":"SPI01","name":"SPI01","description":"Why influenza is a priority for policy makers","account_id":"2bK6rw","ts":1638694920},"SCS02":{"id":"Wj0kJZ","strictid":"SCS02","name":"SCS02","description":"Virus structure and replication in influenza virus, RSV and SARS-CoV-2; latest developments in influenza virus, SARS-CoV-2 and RSV molecular virology","account_id":"2bK6rw","ts":1638694920},"SCS01":{"id":"24amLe","strictid":"SCS01","name":"SCS01","description":"Epidemiology, surveillance and modelling of influenza, RSV disease and COVID-19, including virus evolution and strain selection","account_id":"2bK6rw","ts":1638694920},"WEB02":{"id":"Ak6yJr","strictid":"WEB02","name":"WEB02","description":"Childhood Influenza vaccination and treatment in a COVID-19 era","account_id":"2bK6rw","ts":1638651720},"OPN01":{"id":"WqYk9o","strictid":"OPN01","name":"OPN01","description":"Opening Ceremony\n","account_id":"2bK6rw","ts":1638637200},"KEY04":{"id":"27y68N","strictid":"KEY04","name":"KEY04","description":"COVID coagulopathy in comparison to influenza and pneumococci sepsis","account_id":"2bK6rw","ts":1638694920},"PER01":{"id":"2bzBJX","strictid":"PER01","name":"Permanent Livestream","description":"","account_id":"2bK6rw","ts":0},"SAT03":{"id":"VBXxaB","strictid":"SAT03","name":"SAT03","description":"","account_id":"2bK6rw","ts":1638630000},"SAT02":{"id":"VYeDlQ","strictid":"SAT02","name":"SAT02","description":"INFLUENZA AND COVID-19 Burden of Disease and Prospects for Vaccination","account_id":"2bK6rw","ts":1638622800},"SAT01":{"id":"VBXxPX","strictid":"SAT01","name":"SAT01 ","description":"Post-COVID lockdown era: what are we facing?","account_id":"2bK6rw","ts":1638615600},"WEB01":{"id":"VYeD8w","strictid":"WEB01","name":"WEB01","description":"Vaccination in a COVID-19 era","account_id":"2bK6rw","ts":1638644520},"SAT05":{"id":"ApYQNa","strictid":"SAT05","name":"SAT05","description":"Will be streamed by Roche, not from studio Antwerp, BE","account_id":"2bK6rw","ts":1638709200}}
clevercast items
{"LAN01":{"id":"WEBElL","strictid":"LAN01","name":"Lange testtrailer","description":"","account_id":"2bK6rw","chapters":[]},"TES01":{"id":"W9Jpob","strictid":"TES01","name":"Testtrailer","description":"Test trailer for scheduling Pseudo Live Events","account_id":"2bK6rw","chapters":[]}}
Sun 5 Dec
Sunday
5
December

Sunday 5 December, 10:00 - 11:45 CET

Epidemiology, surveillance and modelling of influenza, RSV disease and COVID-19, including virus evolution and strain selectionSCS01

Time:

Sunday 5 December, 10:00 - 11:45 CET

Track:

Scientific Programme


Chairs:
Colin Russell, Academic Medical Center, University of Amsterdam
Seth Zost, Vanderbilt University Medical Center

Programme:
  1. Influenza A virus undergoes compartmentalized replication in vivo dominated by stochastic bottlenecks

    Andrew Mehle, Microbiology & Immunology, University of Wisconsin-Madison, United States of America
  2. Influenza-associated hospitalisation rates: national burden estimates for 40 countries worldwide, the Burden of Influenza and RSV Disease (BIRD) study

    John Paget, Nivel, The Netherlands
  3. Mapping the antigenic drift of N1 Neuraminidase in A(H1N1) strains from 1977-1991 to understand the childhood imprinting of anti-Neuraminidase antibodies

    Pavithra Daulagala, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR
  4. Human and avian influenza A viruses in Cambodia during the SARS-CoV-2 pandemic, 2020-2021

    Jurre Y. Siegers, Institute Pasteur du Cambodge, Cambodia

Sunday 5 December, 10:00 - 11:45 CET

Virus structure and replication in influenza virus, RSV and SARS-CoV-2; latest developments in influenza virus, SARS-CoV-2 and RSV molecular virologySCS02

Time:

Sunday 5 December, 10:00 - 11:45 CET

Track:

Scientific Programme


Chairs:
Ed Hutchinson, University of Glasgow
Laura Martin-Sancho, Scripps Research

Programme:
  1. Coinfection with influenza A virus and respiratory syncytial virus generates a novel class of viral particles

    Joanne Haney, MRC Centre for Virus Research, University of Glasgow, United Kingdom
  2. Lab adapted vs contemporary RSVs: single amino acid changes modulate F protein mediated cell fusion

    Martin Ludlow, University of Veterinary Medicine Hannover, Germany
  3. Genomic assembly of live attenuated influenza vaccine viruses is mediated via intersegmental RNA:RNA interactions

    Sameer Ayaz, Flu-BPD, BioPharmaceuticals Development, R&D, AstraZeneca, Liverpool, United Kingdom
  4. A new structural approach to study lipid-protein interactions within a viral envelope

    Larisa Kordyukova, Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Russian Federation
  5. Adaptive evolution of PB1 from A(H1N1)pdm09 towards an enhanced compatibility between PB1 and HA

    Filipe Almeida, Antiviral Resistance Lab, Research & Development Unit, Infectious Diseases Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal

Sunday 5 December, 12:00 - 13:45 CET

Keynote lectures on Science based management of epidemics and pandemicsKEY02

Live
Time:

Sunday 5 December, 12:00 - 13:45 CET

Tracks:

Scientific Programme, Keynote lectures


Speaker:
Ab Osterhaus, TiHo, Hannover


Programme:
  1. Household transmission studies

    Ben Cowling, The University of Hong Kong, Hong Kong S.A.R.
  2. Science based management of epidemics and pandemics

    Peter Openshaw, Imperial College London, United Kingdom

Sunday 5 December, 12:00 - 13:45 CET

Innate and adaptive immunity towards influenza, RSV disease and COVID-19SCS06

Time:

Sunday 5 December, 12:00 - 13:45 CET

Track:

Scientific Programme


Chair:
Guus Rimmelzwaan, University of Veterinary Medicine Hannover

Programme:
  1. Effects of metabolic disease on humoral immunity to SARS-CoV-2 infection

    Marcus Tong, School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
  2. HLA-E-dependent antigen-specific memory NK cell responses develop against influenza nucleoprotein and are cross-reactive between antigenically distinct strains

    Stephanie Jost, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, United States of America; Division of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, United States of America
  3. DEVELOPMENT OF EXPERIMENTAL LIVE INFLUENZA VACCINE STRAINS WITH MODIFIED NP AND NS GENES

    Polina Prokopenko, Institute of Experimental Medicine, Russian Federation
  4. T-cell immune responses to live SARS-CoV-2 after natural infection and vaccination

    Irina Isakova-Sivak, Institute of Experimental Medicine, Russian Federation

Sunday 5 December, 16:00 - 17:45 CET

Diagnostic testing in the management of acute respiratory infections in primary and secondary careSCS03

Time:

Sunday 5 December, 16:00 - 17:45 CET

Track:

Scientific Programme


Chairs:
Michael Ison, Northwestern University
Nicole Ngai Yung Tsang, The University of Hong Kong

Programme:
  1. The impact of routine molecular point-of-care testing on hospital acquired COVID-19 infection: a pre and post implementation study

    Robert Livingstone, Division B, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
  2. IFI27 transcription as a prognostic biomarker for COVID-19

    Kirsty Short, The University of Queensland, Australia
  3. Using gargle for monitoring viral shedding in confirmed COVID-19 patients

    Nicole Ngai Yung Tsang, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR

Sunday 5 December, 16:00 - 17:45 CET

Co-infections in influenza, RSV disease and COVID-19SCS04

Time:

Sunday 5 December, 16:00 - 17:45 CET

Track:

Scientific Programme


Chair:
Barbara Rath, Vienna Vaccine Safety Initiative

Programme:
  1. SARS-CoV-2 replication is inhibited by the presence of co-infecting respiratory viruses in differentiated human airway epithelial cells.

    Kieran Dee, Centre for Virus Research, University of Glasgow. United Kingdom
  2. Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology.

    Katarzyna Schewe, Flu-BPD, BioPharmaceuticals Development, R&D, AstraZeneca, Liverpool, United Kingdom
  3. Legionella pneumophila affects the influenza virus-activating host cell protease-repertoire in human cells via two different mechanisms

    Marie Schwerdtner, Institute of Virology, Philipps-University Marburg, Marburg, Germany
  4. Viral co-infections in hospitalised COVID-19 patients recruited to the ISARIC WHO CCP-UK study in Scotland

    Elen Vink, Medical Research Council—University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
Mon 6 Dec
Monday
6
December

Monday 6 December, 10:00 - 11:45 CET

Lessons learned from and prospects for COVID-19 vaccinationSCS07

Time:

Monday 6 December, 10:00 - 11:45 CET

Track:

Scientific Programme


Chairs:
Hanna Nohynek, Finnish Institute for Health and Welfare
Margaret Lugin, BlueWillow Biologics

Programme:
  1. Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination

    Janine Kimpel, Institute of Virology, Medical University of Innsbruck, Austria
  2. Identified Pregnancies and Associated Outcomes Across the Novavax COVID-19 Vaccine Clinical Development Program

    Hadi Beyhaghi, Novavax Inc, United States of America
  3. Nanoemulsion adjuvanted SARS-CoV-2 vaccine induces systemic and mucosal immune response following intranasal vaccination

    Margaret Lugin, BlueWillow Biologics, Ann Arbor, MI, United States of America
  4. Learnings for maximising influenza vaccine uptake during the COVID-19 vaccine roll-out; The Australian Experience in 2021.

    Paul Van Buynder, Department of Medicine, Griffith University, Southport, Queensland, Australia

Monday 6 December, 10:00 - 11:45 CET

Pandemic threats from the animal worldSCS08

Time:

Monday 6 December, 10:00 - 11:45 CET

Track:

Scientific Programme


Chair:
Ron Fouchier, Erasmus MC Rotterdam

Programme:
  1. Adaptive potential of zoonotic avian influenza virus H7N9 to ducks

    Susanne Koethe, Friedrich-Loeffler-Institut, Germany
  2. Defining the Genesis and Pathogenesis of the Avian Influenza Virus

    Lauren E Steele, School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane Australia
  3. Genetic determinants for virulence and adaptation of clade 2.3.4.4 H5N8 viruses in chickens, ducks and mammals

    Elsayed Abdelwhab, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany
  4. Long term circulation of Avian Influenza Viruses Subtype H7 in wild birds in the Azov-Black Sea Region and detection of new hosts

    Denys Muzyka, National Scientific Center - Institute of Experimental and Clinical Veterinary Medicine, Ukraine

Monday 6 December, 12:00 - 13:45 CET

Viral and host factors in the pathogenesis of influenza, RSV diseaseSCS09

Time:

Monday 6 December, 12:00 - 13:45 CET

Track:

Scientific Programme


Chairs:
Peter Openshaw, Imperial College London
Katina Hulme, University of Queensland

Programme:
  1. Mapping influenza A virus cellular defense mechanisms reveals a strategy for evasion of autophagy

    Laura Martin-Sancho, Scripps, United States of America
  2. Precise monitoring of COVID-19 severity and treatment

    Mirella Salvatore, Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America; Department of Population Health Sciences, Weill Cornell Medicine, New York, United States of America
  3. A history of obesity reduces the immune response to influenza virus in a non-canonical NLRP3-dependent manner

    Katina Hulme, School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia
  4. Silencing pulmonary sensory neurons impact influenza pathogenesis

    Nathalie A.J. Verzele, Department of Anatomy and Physiology, The University of Melbourne, Australia; School of Chemistry and Molecular Biosciences, The University of Queensland, Australia
  5. Influenza NS1 protein epigenetically upregulates microRNA-146a to suppress inflammatory responses and promote viral infection

    Bobo Wing Yee Mok, State Key Laboratory for Emerging Infectious Diseases and Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR

Monday 6 December, 12:00 - 13:45 CET

Experimental medicine studies of influenza, RSV disease and COVID-19SCS11

Time:

Monday 6 December, 12:00 - 13:45 CET

Track:

Scientific Programme


Chairs:
Christopher Chiu, Imperial College London
Daniel Goldhill, Imperial College

Programme:
  1. Intranasal M2SR (M2-deficient single replication) live H3N2 influenza investigational vaccine induces HAI responses against drifted influenza strains, as well as T cell responses, mucosal and serum IgA in serosusceptible adults

    Joseph Eiden, FluGen, United States of America
  2. Robust neutralizing antibody and cell mediated immune responses raised by sa-mRNA influenza vaccines co-expressing HA and NA antigens

    Yingxia Wen, Seqirus, United States of America
  3. Safety, tolerability and biological activity of repeated intranasal administration of Ampligen (Poly I:Poly C12U) as potential antiviral treatment in healthy subjects

    Johan L. van der Plas, Centre for Human Drug Research, Leiden, The Netherlands; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
  4. Ensovibep, a potential antiviral COVID-19 treatment, is safe and well tolerated in healthy volunteers: preliminary safety and PK results from a phase 1, multi-part, ascending, single-dose study

    Marianne Soergel, Molecular Partners AG, Schlieren, Switzerland

Monday 6 December, 18:00 - 19:45 CET

Antiviral and immune therapy for influenza, RSV disease and COVID-19SCS10

Time:

Monday 6 December, 18:00 - 19:45 CET

Track:

Scientific Programme


Chair:
Frederick G. Hayden, University of Virginia

Programme:
  1. Host- and viral-targeted antiviral development for SARS-CoV-2 and influenza virus, treating the current pandemic and preparing for the next

    Kris White, Icahn School of Medicine at Mount Sinai, United States of America
  2. Local delivery of interferon beta (SNG001) by inhalation upregulates lung antiviral biomarkers

    Phillip David Monk, Synairgen Research, Southampton General Hospital, Southampton, United Kingdom
  3. Safety, tolerability and pharmacokinetics of ensovibep in patients with mild to moderate COVID-19 - preliminary report of a phase 2a, open-label, single dose escalation study.

    J.L. van der Plas, Centre for Human Drug Research (CHDR), Leiden, The Netherlands; Department of Infectious Diseases, Leiden University Medical Center (LUMC), Leiden, The Netherlands
  4. LAT8881 and other naturally derived cytokine peptides limit respiratory virus replication and severe disease

    Michelle Tate, Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia; Department of Molecular and Translational Sciences, Monash University, Clayton, Victoria, Australia
  5. LAT8881, a novel human growth hormone fragment, is highly effective in reducing SARS-CoV-2 inflammation and lethality in a K18-hACE2 mouse model

    Matt D. Johansen, University of Technology Sydney/Centenary Institute, Australia

Monday 6 December, 18:00 - 19:45 CET

Strategies for future Influenza vaccinationSCS12

Time:

Monday 6 December, 18:00 - 19:45 CET

Track:

Scientific Programme


Chairs:
Florian Krammer, Icahn School of Medicine at Mount Sinai
Nicholas Wu, University of Illinois at Urbana-Champaign

Programme:
  1. The Safety, Immunogenicity, and Efficacy of NVX-CoV2373, a COVID-19 Vaccine, When Co-administered With Seasonal Influenza Vaccines

    Seth Toback, Novavax, United States of America
  2. Quantification of correctly-folded chimeric hemagglutinin in split inactivated influenza A and B virus vaccines

    Eduard Puente-Massaguer, Icahn School of Medicine at Mout Sinai, United States of America
  3. Pre-existing antibodies directed against a heterologous tetramerizing domain boost the immune response against artificially stabilized soluble tetrameric influenza neuraminidase

    João Paulo Portela Catani, VIB-UGent Center for Medical Biotechnology, VIB, Belgium; Department of Biochemistry and Microbiology, Ghent University, Belgium
  4. INFLUENCE OF ADJUVANTS AFTER INFLUENZA VACCINATION IN THE IMMUNODOMINANCE HIERARCHY

    Laura Sanchez-de Prada, National Influenza Center of Valladolid, Spain
  5. Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory

    Lenny Moise, EpiVax, Inc., Providence, RI, United States of America; Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States of America
Tue 7 Dec
Tuesday
7
December

Tuesday 7 December, 10:00 - 11:00 CET

Plenary session dedicated to the work of Young ScientistsPLE03

Live
Time:

Tuesday 7 December, 10:00 - 11:00 CET

Track:

Scientific Programme


Chair:
Marco Goeijenbier, Erasmus MC

Programme:
  1. The Claude Hannoun Best Body of Work Prize 2021

    Ab Osterhaus, TiHo, Hannover, Germany
  2. Immunodominance and antigenic drift: lessons from influenza and SARS-CoV-2

    Seth Zost, Vanderbilt University Medical Center, United States of America
  3. The Innovative Award 2021 supported by Seqirus

    Beverly Taylor, IFPMA, United Kingdom
  4. Public antibody responses to influenza and SARS-CoV-2

    Nicholas Wu, University of Illinois at Urbana-Champaign, United States of America

Tuesday 7 December, 12:00 - 13:45 CET

“Long Covid”: post and acute clinical sequelae of COVID-19SCS13

Time:

Tuesday 7 December, 12:00 - 13:45 CET

Track:

Scientific Programme


Chair:
Susanne Herold, UKGM Gießen

Programme:
  1. IL-6, IL-8 and IFN-β are elevated in individuals with long COVID

    Jane Sinclair, The University of Queensland, School of Chemistry and Molecular Biosciences, St Lucia, Australia
  2. Pulmonary function and quality of life recovery in COVID-19 pneumonia survivors

    Edita Strumiliene, Faculty of Medicine, Vilnius University, Lithuania; Vilnius University Hospital Santaros Klinikos, Lithuania
  3. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19

    Maxime Taquet, University of Oxford, United Kingdom
  4. Recovery after COVID-19 infection

    Merel Hellemons, Erasmus MC, The Netherlands

Tuesday 7 December, 12:00 - 13:45 CET

Strategies for future RSV disease vaccinationSCS14

Time:

Tuesday 7 December, 12:00 - 13:45 CET

Track:

Scientific Programme


Chair:
Rebecca Cox, University of Bergen

Programme:
  1. An Ad26.RSV.preF-based Vaccine is Effective for Prevention of RSV-mediated Lower Respiratory Tract Disease and Reduces Symptom Severity in Vaccine Recipients With RSV Infection: A Phase 2b Study in Older Adults

    Ann R Falsey, University of Rochester School of Medicine, Rochester, NY, United States of America
  2. Immunogenicity Evaluation and Regimen Selection of Prophylactic Ad26.RSV.preF Vaccine Combinations: A Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Phase 1/2a Study in Adults ≥60 Years of Age

    Arangassery Rosemary Bastian, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands
  3. Induction of Broadly Cross-neutralizing Antibody Responses Against A(H3N2) and B Viruses: Results of a Phase 3 Trial of a Recombinant Quadrivalent Hemagglutinin Saponin-adjuvanted Nanoparticle Influenza Vaccine in Older Adults

    Vivek Shinde, Novavax, United States of America
  4. Safety and Tolerability of an Ad26.RSV.preF-based Vaccine in a Randomized, Double-blind, Placebo-controlled, Phase 2b Study in Adults Aged ≥65 Years

    Christy Comeaux, Janssen Vaccines & Prevention BV, Leiden, The Netherlands

Tuesday 7 December, 16:00 - 17:45 CET

Novel and outstanding scientific discoveries: Late BreakersPLE04

Live
Time:

Tuesday 7 December, 16:00 - 17:45 CET

Track:

Scientific Programme


Chair:
Sylvie van der Werf, Institut Pasteur

Programme:
  1. Immunogenicity and efficacy of different heterologous prime-boost vaccination regimens against swine H1N1 influenza viruses

    Anna Parys, Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium
  2. Lower infectious viral load in respiratory samples of vaccinated compared to unvaccinated COVID-19 patients

    Benjamin Meyer, University of Geneva, Switzerland
  3. Ad26.RSV.preF-based vaccine regimen induced antibody Fc-effector functions and neutralization are associated with protection from respiratory syncytial virus infection

    Galit Alter, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA United States of America
  4. Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive Influenza Seasons in the United States

    Constantina Boikos, Seqirus CAN Inc., Canada
  5. The regulatory role of NS gene RNA secondary structure in influenza virus life cycle

    Irina Baranovskaya, Peter the Great St.Petersburg Polytechnic University, Russian Federation; Smorodintsev Research Institute of Influenza, Russian Ministry of Health, Russian Federation
  FILTER